Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
When processed in KEGG for bioinformatic surveillance, this dataset provided additional evidence of a marked metabolic shift associated with GLP-1 agonist treatment, with a fold enrichment of 28.4 affecting the oxidative phosphorylation pathway, representing the presence of 12 significantly downregulated genes relevant to the progression of substrates through this pathway
A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
Enrollment challenges, protocol amendments, and data analysis requirements all contribute to timeline variability
see offer terms
US$ 27.47
US$ 24.12
US$ 20.00
US$ 25.28
